NYSE · BLCO
Bausch + Lomb Corporation
$20.40$0.00 (0.0%)
Bausch + Lomb Corporation’s quoted price sits in the upper half of its reported 52-week range, 4.49% below the high.
Loading market information…
NASDAQ · HROW · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Harrow Health, Inc.’s quoted price sits in the lower half of its reported 52-week range, 45.32% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Harrow Health, Inc.’s next earnings report is currently expected on Nov 9, 2026, with estimated earnings per share of $0.17. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Harrow Health, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 8, 2025 | -$0.50-2,600.0% vs estimate | $47.83M-16.08% vs estimate |
|---|
| Q4 2024 | Mar 27, 2025 | $0.24+192.68% vs estimate | $66.83M+8.15% vs estimate |
|---|
| Q3 2024 | Nov 13, 2024 | -$0.12-140.0% vs estimate | $49.26M-6.71% vs estimate |
|---|
THE ANALYST VIEW
10 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $66.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$20.40$0.00 (0.0%)
Bausch + Lomb Corporation’s quoted price sits in the upper half of its reported 52-week range, 4.49% below the high.
$100.40+$3.36 (+3.46%)
Kodiak Sciences Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.46% below the high.
$74.20+$2.15 (+2.98%)
Tarsus Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 18.93% below the high.
$7.31+$0.02 (+0.27%)
Ocular Therapeutix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.54% below the high.
$8.24+$0.26 (+3.26%)
Oculis Holding AG’s quoted price sits in the lower half of its reported 52-week range, 76.1% below the high.
$10.72-$0.40 (-3.6%)
Turn Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 34.83% below the high.
$0.49-$0.05 (-9.43%)
Outlook Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.57% below the high.
$0.38+$0.00 (+0.69%)
EyePoint Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.01% below the high.
